BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics (ANTX)AN2 TherapeuticsEarnings

Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease Positive non-human primate efficacy and favorable Phase 1 clinical pharmacokinetics

Related news

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-03-17 20:00 EST

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

SPROSpero Therapeutics2026-08-04 21:01 EST

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

ASMBAssembly Biosciences2026-05-07 20:00 EST

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

VIRIVirios Therapeutics2026-08-13 12:30 EST

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

SPROSpero Therapeutics2026-05-05 16:05 EST

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

VIRIVirios Therapeutics2026-03-18 12:30 EST

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

ASMBAssembly Biosciences2026-08-13 20:00 EST

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

AVIRAtea2026-08-12 20:05 EST

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

IMNNImunon2026-08-11 12:00 EST

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...

Recent company news

ANTXAN2 Therapeutics2026-08-11 20:00 EST

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-05-07 20:01 EST

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Stock data

Close
5.73 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States